| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Larimar Therapeutics, Inc. (LRMR) has 6 insiders with recent SEC Form 4 filings, including 21 buys and 3 sells. LRMR is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 9.54M | $38.59M | - | |
| Dir | 664.8K | $2.69M | - | |
| Dir | 19.0K | $76.9K | - | |
| Dir | 19.0K | $76.9K | - | |
| Dir | 19.0K | $76.9K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 11, 2017 | Kim Dennis D | Chief Medical Officer | Buy | 10,000 | $4.40 | $44,000.00 | +324.0% | |
| Dec 19, 2016 | Heller Frances K | Director | Buy | 10,000 | $3.23 | $32,290.00 | +50.0% | |
| Nov 15, 2016 | Heller Frances K | Director | Buy | 10,000 | $3.54 | $35,434.00 | +100.0% | |
| Aug 29, 2016 | Hughes Thomas E. | President And CEO | Buy | 10,000 | $3.00 | $29,987.00 | +18.5% | |
| Jul 26, 2016 | Allen Patricia L | Chief Financial Officer | Buy | 16,000 | $3.12 | $49,861.80 | +104.0% | |
| Jul 22, 2016 | Hughes Thomas E. | President And CEO | Buy | 5,000 | $3.02 | $15,104.00 | +10.2% | |
| Jul 22, 2016 | Heller Frances K | Director | Buy | 10,000 | $2.99 | $29,900.00 | New | |
| Jul 20, 2016 | Flynn James E62 | 10% Owner, Possible Member Of 10% Group | Sell | 1,341,499 | $3.31 | $4,442,776.39 | -43.9% | |
| Feb 12, 2016 | Flynn James E62 | 10% Owner, Possible Member Of 10% Group | Buy | 64,545 | $6.25 | $403,186.80 | +2.2% | |
| Feb 11, 2016 | Flynn James E62 | 10% Owner, Possible Member Of 10% Group | Buy | 267,493 | $6.02 | $1,609,667.67 | +3.1% |